Study of the Efficacy and Safety of MEDI4893
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/19/2018 |
| Start Date: | October 10, 2014 |
| End Date: | October 2, 2018 |
A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused
by Staphylococcus aureus in high-risk patients
by Staphylococcus aureus in high-risk patients
Inclusion Criteria:
- Colonized with Staphylococcus aureus, expected to require prolonged intubation and
mechanical ventilation, without any evidence of active pneumonia.
Exclusion Criteria:
- Staphylococcal disease at randomisation; lung injury score consistent with pneumonia;
current lung disease; chronic tracheostomy patients; currently receiving systemic
anti-staphylococcal antibiotics; moribund patients.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials